全文获取类型
收费全文 | 2038492篇 |
免费 | 134947篇 |
国内免费 | 5380篇 |
专业分类
耳鼻咽喉 | 26281篇 |
儿科学 | 65740篇 |
妇产科学 | 52542篇 |
基础医学 | 308815篇 |
口腔科学 | 55659篇 |
临床医学 | 190400篇 |
内科学 | 392522篇 |
皮肤病学 | 43332篇 |
神经病学 | 164027篇 |
特种医学 | 72959篇 |
外国民族医学 | 515篇 |
外科学 | 282051篇 |
综合类 | 37070篇 |
现状与发展 | 4篇 |
一般理论 | 658篇 |
预防医学 | 173308篇 |
眼科学 | 44452篇 |
药学 | 149979篇 |
7篇 | |
中国医学 | 4998篇 |
肿瘤学 | 113500篇 |
出版年
2021年 | 19254篇 |
2019年 | 19852篇 |
2018年 | 29258篇 |
2017年 | 21446篇 |
2016年 | 22899篇 |
2015年 | 25983篇 |
2014年 | 34431篇 |
2013年 | 51975篇 |
2012年 | 75664篇 |
2011年 | 80095篇 |
2010年 | 44923篇 |
2009年 | 40042篇 |
2008年 | 71235篇 |
2007年 | 76246篇 |
2006年 | 74505篇 |
2005年 | 72575篇 |
2004年 | 69437篇 |
2003年 | 65603篇 |
2002年 | 61796篇 |
2001年 | 83690篇 |
2000年 | 85593篇 |
1999年 | 72016篇 |
1998年 | 20388篇 |
1997年 | 18064篇 |
1996年 | 17843篇 |
1995年 | 16899篇 |
1994年 | 15663篇 |
1992年 | 56158篇 |
1991年 | 56228篇 |
1990年 | 54798篇 |
1989年 | 52549篇 |
1988年 | 48478篇 |
1987年 | 47418篇 |
1986年 | 44960篇 |
1985年 | 42887篇 |
1984年 | 32184篇 |
1983年 | 27374篇 |
1982年 | 15891篇 |
1979年 | 29425篇 |
1978年 | 20853篇 |
1977年 | 17068篇 |
1976年 | 16966篇 |
1975年 | 18415篇 |
1974年 | 21981篇 |
1973年 | 21323篇 |
1972年 | 19741篇 |
1971年 | 18635篇 |
1970年 | 17308篇 |
1969年 | 15941篇 |
1968年 | 15160篇 |
排序方式: 共有10000条查询结果,搜索用时 0 毫秒
1.
2.
3.
Jose M. Morales Jose Angel Martinez-Flores Manuel Serrano Maria José Castro Francisco Javier Alfaro Florencio García Miguel Angel Martínez Amado Andrés Esther González Manuel Praga Estela Paz-Artal Antonio Serrano 《Journal of the American Society of Nephrology : JASN》2015,26(3):735-745
In the current immunosuppressive therapy era, vessel thrombosis is the most common cause of early graft loss after renal transplantation. The prevalence of IgA anti–β2-glycoprotein I antibodies (IgA-aB2GPI-ab) in patients on dialysis is elevated (>30%), and these antibodies correlate with mortality and cardiovascular morbidity. To evaluate the effect of IgA-aB2GPI-ab in patients with transplants, we followed all patients transplanted from 2000 to 2002 in the Hospital 12 de Octubre prospectively for 10 years. Presence of IgA-aB2GPI-ab in pretransplant serum was examined retrospectively. Of 269 patients, 89 patients were positive for IgA-aB2GPI-ab (33%; group 1), and the remaining patients were negative (67%; group 2). Graft loss at 6 months post-transplant was significantly higher in group 1 (10 of 89 versus 3 of 180 patients in group 2; P=0.002). The most frequent cause of graft loss was thrombosis of the vessels, which was observed only in group 1 (8 of 10 versus 0 of 3 patients in group 2; P=0.04). Multivariate analysis showed that the presence of IgA-aB2GPI-ab was an independent risk factor for early graft loss (P=0.04) and delayed graft function (P=0.04). There were no significant differences regarding patient survival between the two groups. Graft survival was similar in both groups after 6 months. In conclusion, patients with pretransplant IgA-aB2GPI-ab have a high risk of early graft loss caused by thrombosis and a high risk of delayed graft function. Therefore, pretransplant IgA-aB2GPI-ab may have a detrimental effect on early clinical outcomes after renal transplantation. 相似文献
4.
5.
6.
7.
Eric S. Zhou Larissa Nekhlyudov Sharon L. Bober 《Translational andrology and urology》2015,4(2):218-231
There is a large and growing population of long-term cancer survivors. Primary care physicians (PCPs) are playing an increasingly greater role in the care of these patients across the continuum of cancer survivorship. In this role, PCPs are faced with the responsibility of managing a range of medical and psychosocial late effects of cancer treatment. In particular, the sexual side effects of treatment which are common and have significant impact on quality of life for the cancer survivor, often go unaddressed. This is an area of clinical care and research that has received increasing attention, highlighted by the presentation of this special issue on Cancer and Sexual Health. The aims of this review are 3-fold. First, we seek to overview common presentations of sexual dysfunction related to major cancer diagnoses in order to give the PCP a sense of the medical issues that the survivor may present with. Barriers to communication about sexual health issues between patient/PCPs in order are also described in order to emphasize the importance of PCPs initiating this important conversation. Next, we provide strategies and resources to help guide the PCP in the management of sexual dysfunction in cancer survivors. Finally, we discuss case examples of survivorship sexual health issues and highlight the role that a PCP can play in each of these case examples. 相似文献
8.
Stelter K. Theodoraki M. N. Becker S. Tsekmistrenko V. Olzowy B. Ledderose G. 《European archives of oto-rhino-laryngology》2015,272(3):639-639
European Archives of Oto-Rhino-Laryngology - 相似文献
9.
Rosario Gulias-Cañizo Anell Lagunes-Guillén Arturo González-Robles Erika Sánchez-Guzmán Federico Castro-Muñozledo 《Burns : journal of the International Society for Burn Injuries》2019,45(2):398-412
Background
Since recent reports have shown that (-)-Epigallocatechin-3-gallate (EGCG) could be used for treating proliferative and inflammatory disorders, we explored its use for the management of corneal chemical burns.Materials and methods
Initially, EGCG was assayed on the rabbit corneal epithelial cell line RCE1(5T5) to establish the best testing conditions, and to avoid unwanted outcomes in the experimental animals. Then, we studied its effects on cell proliferation, cell cycle progression and cell differentiation. Afterwards, we instilled EGCG in experimental grade II corneal alkali burns in mice, three times a day up to 21 days, and evaluated by slit lamp examination and histological sections of corneal epithelial, corneal endothelial and stromal edema, as well as the presence of inflammatory cells and neovascularization.Results
EGCG reduced cell growth and led to a decline in the proportion of proliferative cells in a concentration dependent manner. At 10 μM, EGCG promoted cell differentiation, an effect not related with apoptosis or cytotoxicity. When 10 μM EGCG was instilled in corneal alkali burns in mice three times a day up to 21 days, EGCG significantly reduced corneal opacity and neovascularization. The improved clinical appearance of the cornea was associated to a controlled epithelial growth; epithelial morphology was similar to that observed in normal epithelium and contrasted with the hyperproliferative, desquamating epithelium observed in control burn wounds. EGCG reduced corneal, stromal and endothelial edema, and wound inflammation.Conclusion
This work constitutes the first evidence for the use of EGCG in the acute phase of a corneal alkali burn, representing a possible novel alternative to improve patient outcomes as an add-on therapy. 相似文献10.